繁體
简体中文
繁體中文

浸入科技 IMMR 深 滬

等待開盤 11-19 09:30:00 美东时间

6.83

-0.040

-0.58%

华盛通華盛通
立即下載
  • 最 高6.93
  • 今 開6.85
  • 成交量 8.39万股
  • 最 低 6.75
  • 昨 收 6.87
  • 總市值 22.96万
  • 52周最高 8.05
  • 市盈率 靜 17.38
  • 換手率 249.53%
  • 52周最低 5.10
  • 委 比 33.37%
  • 總股本 3.36万
  • 歷史最高 17.055
  • 量 比 0.77
  • 振 幅 2.62%
  • 歷史最低 0.45
  • 每 手 1
  • 風險率 0.60%

個股概要

財務分析

公司資料

相關新聞

分紅派息

  • 分時圖
  • 日k
  • 周k
  • 月k

相關新聞

更多
  • Immersion Receives Additional Delinquency Notice From Nasdaq

    Immersion Corporation ("Immersion", the "Company", "we", "us" or "our") (NASDAQ:IMMR), a leading provider of technologies for haptics, today announced that, on March 24, 2026, the Company received an additional

    03-28 04:02

  • Immersion Obtains Nasdaq Staff Determination Letter

    Immersion Corporation ("Immersion", the "Company", "we", "us" or "our") (NASDAQ:IMMR), a leading provider of technologies for haptics, today announced that, on February 10, 2026, the Company received a Staff

    02-14 05:03

  • NetEase, Nvidia And 3 Stocks To Watch Heading Into Monday

    U.S. stock futures trading slightly lower. NetEase's executive VP retires. Obook reports earnings. Immersion receives delinquency notice.

    2025-12-29 16:21

  • Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

    Immuneering Corporation announced positive Phase 2a data for atebimetinib in combination with modified Gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients, showing 94% overall survival and 72% progression-free survival at 6 months, with a 39% overall response rate. Atebimetinib demonstrated favorable tolerability, with no Grade 3+ events in most adverse event categories. The company plans a pivotal trial for 2026.

    2025-06-17 10:00

  • Immuneering to Present at the Jefferies Global Healthcare Conference

    Immuneering Corporation's management will present at the Jefferies Global Healthcare Conference on June 5, 2025, to discuss the company's pipeline, platform, and business strategy. The presentation will be webcast live and archived on Immuneering's website.

    2025-05-29 12:00

  • Immersion Stock Is Surging Wednesday: What's Behind The Move?

    Immersion Corp (NASDAQ:IMMR) shares are trading higher on the heels of the company’s second-quarter financial results. Here’s a rundown of the print. What Happened: Immersion reported second-quarter revenue of $99.42 million, up from $6.98 million in the prior year’s period. The haptics technology c...

    2024-08-21 21:28

  • Sector Update: Tech Stocks Flat to Higher Premarket Wednesday

    09:07 AM EDT, 08/21/2024 (MT Newswires) -- Technology stocks were flat to higher premarket Wednesday with the SPDR S&P Semiconductor ETF (XSD) inactive and the Technology Select Sector SPDR Fund (XLK) recently up 0.2%. Keysight Technologies (KEYS) shares were up more than 11% after it reported a les...

    2024-08-21 21:07

  • Immersion Q2 Non-GAAP Earnings, Sales Increase

    05:50 PM EDT, 08/20/2024 (MT Newswires) -- Immersion (IMMR) reported Q2 non-GAAP earnings late Tuesday of $1.14 per diluted share, up from $0.26 a year earlier. One analyst polled by Capital IQ expected $0.17. Revenue for the quarter that ended June 30 was $99.4 million, up from $7 million a year ea...

    2024-08-21 05:50

  • Immersion Q2 2024 Adj EPS $1.14, Up From $0.26 Prior Year; Sales $99.42M, Up From $6.98M Prior Year

    On June 10, 2024, the Company closed certain transactions with Barnes & Noble Education, Inc. As part of the transactions, the Company acquired 42% of all outstanding common shares of Barnes & Noble Education, as well as control over Barnes & Noble Education through the five Immersion-appointed boar...

    2024-08-21 05:27